Calculate intrinsic business value using Discounted Cash Flow analysis. Project free cash flows, terminal value, and perform sensitivity analysis for M&A and investment decisions.
Try an example:
Enter your DCF inputs to see valuation results.
A DCF (Discounted Cash Flow) valuation estimates what a business is worth today by projecting its future free cash flows and discounting them back to present value using the weighted average cost of capital (WACC). It is the most widely used intrinsic valuation method in M&A, equity research, and corporate finance because it values a company based on cash generation rather than market sentiment.
A Discounted Cash Flow (DCF) model values a business by projecting free cash flows over 5-10 years, calculating a terminal value using the Gordon Growth Model, and discounting everything back to present value at the company's WACC. Terminal value typically accounts for 60-80% of total DCF value. Most analysts use 2-3% terminal growth and vary WACC by +/-1-2% in sensitivity analysis to produce a valuation range rather than a single estimate.
DCF analysis is considered the gold standard of intrinsic valuation methods in corporate finance. According to the CFA Institute, DCF is fundamental to investment analysis because it directly connects a company's value to its ability to generate cash for shareholders.
The methodology was popularized by John Burr Williams in his 1938 book "The Theory of Investment Value" and refined by Professor Aswath Damodaran at NYU Stern, whose work is considered the authoritative reference for valuation practitioners. The core principle is straightforward: a business is worth the present value of all future cash flows it will generate, discounted at an appropriate rate reflecting the risk of those cash flows.
DCF analysis is particularly valuable for M&A transactions, leveraged buyouts, and fundamental stock analysis because it forces analysts to make explicit assumptions about growth, profitability, and risk. Unlike market-based multiples, DCF valuations are independent of current market sentiment and focus entirely on a company's fundamental value drivers. Related approaches include Net Present Value (NPV) for project-level decisions and Internal Rate of Return (IRR) for comparing investment opportunities against WACC hurdle rates.
The DCF model consists of two key components: the present value of projected free cash flows during an explicit forecast period (typically 5-10 years) and the terminal value representing all cash flows beyond the forecast period. Understanding how these components interact with the weighted average cost of capital (WACC) is essential for producing reliable valuations.
A two-stage DCF model uses a high growth rate for the first 5-10 years and then a lower terminal growth rate (2-3%) in perpetuity. This is more realistic than a single growth rate because most companies cannot sustain high growth indefinitely. For businesses with a patent cliff, product cycle, or competitive transition, analysts often use a three-stage model with an explicit decline phase between the high-growth and terminal periods.
A reverse DCF inverts the standard process: instead of projecting cash flows to estimate value, you start with the current market price and solve for the growth rate the market is implying. If a stock trades at $100 per share and the reverse DCF shows the market expects 25% annual FCF growth for 10 years, you can assess whether that growth expectation is realistic. This technique is especially useful for evaluating whether high-growth SaaS companies or technology stocks are priced reasonably relative to their fundamental prospects.
The discount rate is the single most impactful input in any DCF model. A 1% change in WACC can shift enterprise value by 10-15%. As of January 2026, the median cost of capital for a US firm is 7.79% according to Damodaran's dataset. The table below shows median WACC values by sector, based on data compiled by Professor Aswath Damodaran at NYU Stern (January 2026 dataset, US companies).
Use the WACC Calculator to compute a company-specific rate, or reference these benchmarks as a starting point.
| Industry | Median WACC | Typical Range | Key Driver |
|---|---|---|---|
| Software (System & Application) | 9.3% | 8-11% | High equity beta, minimal debt |
| Software (Internet/SaaS) | 10.7% | 9-13% | Growth uncertainty, no debt |
| Drugs / Pharma | 7.9% | 7-9% | Patent cliffs, regulatory risk |
| Healthcare Products | 8.1% | 7-10% | Regulatory approval cycles, reimbursement risk |
| Machinery / Manufacturing | 7.7% | 7-9% | Cyclicality, capital intensity |
| Food Processing | 5.8% | 5-7% | Stable demand, brand moats |
| Utility (General) | 4.4% | 4-5% | Regulated returns, high leverage |
| Oil/Gas (Integrated) | 5.1% | 5-6% | Commodity exposure, high debt capacity |
| Retail (General) | 7.3% | 7-8% | Competition, margin pressure |
| Telecom Services | 5.4% | 5-6% | Recurring revenue, high capex |
Source: Damodaran Online, NYU Stern School of Business (January 2026 dataset). WACC estimates based on cost of equity ( CAPM with sector betas) and after-tax cost of debt. Private companies typically add 2-4% illiquidity premium above public-company WACC.
Enterprise Value = Sum of PV(FCFs) + PV(Terminal Value)
Where each component is calculated as:
PV(FCF_n) = FCF_0 x (1 + g)^n / (1 + WACC)^n
Terminal Value = FCF_n x (1 + g_term) / (WACC - g_term)
To calculate a DCF valuation: (1) start with the company's normalized free cash flow, (2) project FCF forward 5-10 years using an appropriate growth rate, (3) calculate terminal value using the Gordon Growth Model (TV = FCF x (1+g) / (WACC-g)), (4) discount all future values back to the present at the company's WACC, and (5) subtract net debt to arrive at equity value. For private companies, add a 2-4% illiquidity premium to the discount rate.
Start with the company's current Free Cash Flow (FCF), calculated as Operating Cash Flow minus Capital Expenditures. Normalize for one-time items and ensure FCF is sustainable.
Apply a reasonable growth rate to project FCF over your forecast period (typically 5-10 years). Growth rates should reflect industry dynamics, competitive position, and historical performance.
Calculate the Weighted Average Cost of Capital (WACC) using the company's capital structure, cost of equity (via CAPM), and cost of debt. This reflects the required return for investors.
Use the Gordon Growth Model to calculate terminal value, representing all cash flows beyond the forecast period. Terminal growth rate should not exceed long-term GDP growth (typically 2-3%).
Discount all projected FCFs and terminal value back to present using WACC. Sum these values to arrive at Enterprise Value.
Subtract net debt (total debt minus cash) from Enterprise Value to calculate Equity Value. Divide by shares outstanding for per-share intrinsic value.
DCF analysis values a company based on intrinsic cash flows, independent of market sentiment, while comparable company analysis uses market multiples from similar public companies. DCF is preferred for M&A and LBO analysis where intrinsic value matters; comparables are faster and better suited for early-stage companies without stable cash flows. Most professional valuations use both methods and compare results to triangulate fair value.
While both methods are essential tools in a valuation toolkit, they serve different purposes and have distinct strengths. Understanding when to use each approach is critical for accurate valuations.
Most professional valuations use both methods, comparing DCF results against market-based multiples to triangulate fair value. Significant discrepancies between the two approaches warrant investigation into underlying assumptions or market inefficiencies.
The five most common DCF mistakes are: using revenue growth as a proxy for free cash flow growth, setting terminal growth above long-term GDP growth (2-3%), ignoring working capital requirements that reduce FCF, mismatching cash flow currency with discount rate currency, and presenting a single-point estimate without sensitivity analysis. Avoiding these errors significantly improves valuation reliability.
Even experienced analysts make these errors. According to McKinsey's "Valuation" (8th edition, 2025), flawed DCF assumptions are the leading cause of valuation disputes in M&A transactions.
Revenue growth and free cash flow growth diverge significantly in capital-intensive businesses. A company growing revenue at 20% may see FCF grow at only 8-10% due to reinvestment needs. Always project FCF margins separately from top-line growth.
Setting terminal growth above long-term GDP growth (2-3%) implies the company will eventually exceed the economy. The Federal Reserve targets 2% long-term inflation. Terminal growth of 2-2.5% is appropriate for most businesses; only companies with exceptional pricing power may justify 3%.
Growing companies require additional working capital investment that reduces FCF. A retailer growing 10% annually may need 3-5% of revenue as incremental working capital, reducing effective FCF growth by 1-2 percentage points.
Cash flows denominated in EUR must be discounted at a EUR-denominated WACC. Using a USD WACC for EUR cash flows introduces a currency mismatch that can distort value by 15-25% in volatile FX environments.
A single-point DCF estimate gives false precision. Professional analysts always present a valuation range by varying WACC (+/- 1-2%) and terminal growth (+/- 0.5%). Our sensitivity tab above automates this analysis.
A software company generating $100M in FCF is being valued for acquisition. The acquirer projects 20% growth for 5 years tapering to 3% terminal growth, using 12% WACC.
Year 1-5 FCFs: $120M, $144M, $173M, $207M, $249M
Terminal Value: $249M x 1.03 / (0.12 - 0.03) = $2.85B
PV of FCFs: $626M
PV of TV: $1.62B
Enterprise Value: $2.24B (22.4x FCF)
The high growth assumptions result in a premium multiple. Sensitivity analysis shows value ranges from $1.8B to $3.0B depending on growth and discount rate assumptions.
A mature manufacturing company with $50M FCF, 3% growth expectations, 2% terminal growth, and 9% WACC representing lower risk.
Year 1-7 FCFs: $51.5M to $61.5M (3% annual growth)
Terminal Value: $61.5M x 1.02 / (0.09 - 0.02) = $896M
PV of FCFs: $286M
PV of TV: $490M
Enterprise Value: $776M (15.5x FCF)
Lower growth but also lower risk results in a more modest multiple. Terminal value represents 63% of total value, within acceptable range for stable businesses.
A B2B SaaS company with $15M ARR, 35% growth, 10% FCF margin ($1.5M FCF). The SaaS valuation uses 13% WACC (reflecting high equity cost) and 3% terminal growth. FCF margin is projected to expand to 25% as growth normalizes.
Initial FCF: $1.5M, growing 35% for 3 years then tapering to 15%
Year 10 FCF: $8.2M (as margins expand and growth stabilizes)
Terminal Value: $8.2M x 1.03 / (0.13 - 0.03) = $84.5M
PV of FCFs: $22.8M | PV of TV: $28.8M
Enterprise Value: $51.6M (3.4x ARR)
The implied 3.4x ARR multiple is consistent with SaaS companies growing 30-40% with Rule of 40 scores above 45. Higher-growth SaaS companies may trade at 8-15x ARR, reflecting market premiums not captured in standalone DCF.
A consumer products company preparing for IPO with $200M FCF, expected 8% growth for 10 years, 2.5% terminal growth, and 10% WACC.
Year 10 FCF: $431M (after 8% annual growth)
Terminal Value: $431M x 1.025 / (0.10 - 0.025) = $5.89B
PV of FCFs: $1.53B
PV of TV: $2.27B
Enterprise Value: $3.80B (19.0x FCF)
With $500M net debt and 100M shares, equity value is $3.30B or $33 per share. IPO pricing would likely target a 10-15% discount to this intrinsic value.
A mid-cap pharmaceutical company with $75M FCF, a key drug patent expiring in 5 years, and a pipeline expected to stabilize revenue after year 7. Uses a two-stage model: 12% growth (years 1-5) declining to 4% (years 6-10), then 2% terminal growth, with 7.9% WACC reflecting pharma sector risk.
Stage 1 (Yr 1-5): $84M, $94M, $105M, $118M, $132M (12% growth)
Stage 2 (Yr 6-10): $137M, $143M, $148M, $154M, $161M (4% growth)
Terminal Value: $161M x 1.02 / (0.079 - 0.02) = $2.78B
PV of FCFs: $838M | PV of TV: $1.47B
Enterprise Value: $2.31B (30.8x FCF)
The two-stage approach captures the patent cliff reality. Terminal value is 64% of total value, within normal range. Adding a 15-30% illiquidity discount for a private pharma company would reduce the valuation to $1.6B-$2.0B. Compare against P/E multiples for pharma peers trading at 15-25x earnings as a cross-check.
A DCF valuation produces an enterprise value range, not a single number. Compare your base case against the sensitivity table extremes to establish a realistic valuation corridor. If the stock trades below even the conservative (high-WACC, low-growth) scenario, the margin of safety is strong. If it trades above the optimistic scenario, the market is pricing in growth beyond what fundamentals support.
Indicates the market expects low or declining growth. Common for mature industrials, utilities, and companies with limited reinvestment opportunities. Verify whether the low multiple reflects genuine value or structural decline in the business.
Typical for stable businesses with moderate growth (5-10% annually). Most M&A transactions for profitable SMBs and mid-market companies fall in this range. Cross-check against EBITDA multiples to validate.
Implies the market expects sustained high growth (15%+ annually) or significant margin expansion. Common for technology and SaaS companies. Scrutinize whether the growth assumptions are achievable over your full projection period.
If the current stock price implies a growth rate significantly above the company's historical average or industry trend, the market may be pricing in overly optimistic expectations. Compare the implied growth from a reverse DCF against the company's trailing 3-year revenue growth rate and the sector's median growth as a reality check.
This means most of the value lies beyond your explicit forecast period, increasing model uncertainty. Consider extending your projection period, using more conservative terminal growth, or validating with comparable multiples as a cross-check.
The main limitations of DCF analysis are: terminal value sensitivity (representing 60-80% of total value), subjective WACC estimation, growth rate forecasting uncertainty beyond 2-3 years, poor applicability to early-stage or highly cyclical companies, and inability to capture strategic value such as synergies or control premiums in M&A contexts.
While DCF is theoretically sound, practitioners must understand its limitations to avoid misleading conclusions. Warren Buffett famously noted that DCF is the only correct way to value a business, but acknowledged it can be extremely difficult to apply correctly.
Terminal value often represents 60-80% of total DCF value, yet it depends heavily on the terminal growth rate assumption. A 0.5% change in terminal growth can swing value by 10-20%, making the model highly sensitive to a single subjective input.
The weighted average cost of capital requires estimating cost of equity (using CAPM or similar models), which involves subjective inputs like equity risk premium and beta. Small WACC changes significantly impact valuation.
Projecting growth rates beyond 2-3 years is inherently uncertain. Companies rarely maintain high growth rates indefinitely, and analysts often overestimate growth persistence. Historical growth is a poor predictor of future growth.
DCF works poorly for early-stage companies with negative cash flows, highly cyclical businesses, financial institutions, and companies undergoing significant transformation. Alternative methods may be more appropriate in these cases.
DCF values standalone cash flows but doesn't capture strategic value such as synergies, optionality, or control premiums that may exist in M&A contexts. Acquirers often pay premiums above DCF value for strategic reasons.
Pair this DCF analysis with the EBITDA Calculator to validate earnings inputs, and the WACC Calculator to determine an accurate discount rate. Compare your DCF result against P/E ratio multiples to triangulate fair value. You can also cross-check against valuation multiples and book value for a more complete picture.
DCF analysis is the most theoretically sound intrinsic valuation method, directly linking company value to its cash-generating ability rather than market sentiment or comparable transactions.
Terminal value typically represents 60-80% of DCF value. Keep terminal growth rates at or below long-term GDP growth (2-3%) and always perform sensitivity analysis to understand the impact of assumptions.
Use the WACC calculator to determine an appropriate discount rate. WACC should reflect the company's specific risk profile, capital structure, and industry benchmarks.
Always bridge from Enterprise Value to Equity Value by subtracting net debt. For public companies, divide by diluted shares outstanding to calculate per-share intrinsic value.
Apply margin of safety principles from Benjamin Graham - value investors typically require 20-30% discount to intrinsic value before investing to protect against estimation errors.
Cross-validate DCF results against multiple approaches: EPS for earnings quality, dividend yield for income analysis, and ROI for return assessment. The best valuations triangulate from DCF, comparable multiples, and asset-based methods to establish a defensible value range.
Calculate OER and NOI for real estate properties
Calculate capitalization rate and property value
Calculate gross and net rental yield
Estimate property taxes and effective rates
Rental Property Guide
In-depth guide with examples, benchmarks, and interactive calculators